Advertisement

Primäre und sekundäre Prävention

  • U.-S. Albert
  • K.-D Schulz
Part of the Onkologie Aktuell book series (ONKAKTUELL)

Zusammenfassung

Das normale Brustdrüsengewebe wird durch ein komplexes Zusammenspiel von Steroid-und Proteohormonen reguliert (Braendle u. Schulz 1998; Tabelle 8.1). Proliferation und Funktion werden allerdings nicht nur endokrin, sondern auch auto-und parakrin gesteuert. Eine wesentliche Rolle spielen dabei eine Reihe von Polypeptidwachstumsfaktoren und die durch sie aktivierten intrazellulären Signalwege. Eine Bedeutung dieser Regelkreise für die maligne Transformation und Progression ist bekannt, aber bis heute nicht hinreichend geklärt. Monoklonale Antikörper gegen derartige Wachstumsfaktorrezeptoren, wie z.B. HER2 (human epidermal-growth-factor-receptor 2) werden therapeutisch zunehmend relevant (Cobleigh et al. 1999). Trotz der inzwischen bekannten Vielschichtigkeit hormonaler Regulationen beim Mammakarzinom stützen sich therapeutische und damit auch präventive Ansätze immer noch fast ausschließlich auf die Wechselwirkung zwischen Östrogenen und Gestagenen bzw. deren Antagonisierung (Henderson et al. 1988).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adzersen KH, Eustachi A, Gerhard I (1999) Stellungnahme zu Umwelt, Ernährung und Brustkrebs Arbeitsgemeinschaft Naturheilkunde und Umweltmedizin (NATUM). Frauenarzt 10:233–1239Google Scholar
  2. Bange J, Zwick E, Ullrich A (2001) Molecular targets for breast cancer therapy and prevention. Nature Medicine 7(5): 548–552PubMedGoogle Scholar
  3. Bergman L, Beelen MLR, Gallee MPW, Hollema H, Benraadt J, van Leeuwen FE and the Comprehensive Cancer Centres „Alert Group“ (2000) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 356:881–887PubMedGoogle Scholar
  4. Boyd NF, Greenberg C, Lockwood G et al. (1997) Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. J Natl Cancer Inst 89:488–496PubMedGoogle Scholar
  5. Braendle W, Schulz KD (Hrsg) (1998) Hormone und Mammakarzinom: Konsensus-Meeting Berlin 1997. Aktuelle Onkologie Bd. 100. München, Bern, Wien, New York: Zuck-schwerdtGoogle Scholar
  6. Chlebowski RT (2000) Reducing the risk of breast cancer. New Engl J Med 343 (3): 191–198PubMedGoogle Scholar
  7. Cobleigh MA, Vogel CL, Tripathy D et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overex-pressing metastatic breast cancer that have progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (9): 2639–2648PubMedGoogle Scholar
  8. Conley B, O’Shaughnessy J, Prindivilli S et al. (2000) Pilot trial of safety, tolerability, and retinoid levels of N-(4-hydroxy-phenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol 18: 275–283PubMedGoogle Scholar
  9. Cummings SR, Eckert S, Krueger KA et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281: 2189–2197 (Erratum: JAMA (1999) 282: 2124)PubMedGoogle Scholar
  10. Dragnev KH, Rigas JR, Dmitrovsky E (2000) The retinoids and cancer prevention mechanisms. The Oncologist 5:361–368PubMedGoogle Scholar
  11. Dunn BK, Ford LG (2001) From adjuvant therapy to breast cancer prevention: bcpt and star Breast J 7 (3): 144–157Google Scholar
  12. Fisher B et al. (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical adjuvant Breast and Bowel Projekt P-1 Study. J Natl Cancer Inst 90:1371–1388PubMedGoogle Scholar
  13. Friedenreich CM, Thune I, Brinton AA, Albanes D (1998) Epidemiologic issues related to the association between physical activity and breast cancer. Cancer 83 (suppl): 600–610PubMedGoogle Scholar
  14. Frost MH, Schaid DJ, Sellers TA et al. (2000) Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284 (3): 319–324PubMedGoogle Scholar
  15. Gail MH, Constantino JP, Bryant J et al. (1999) Weighing the risks and benefits of tamoxifen for preventing breast cancer. J Natl Cancer Inst 91:1829–1846PubMedGoogle Scholar
  16. Goldstein SR (1999) Effects of SERMs on breast tissue. J Endocrinol Invest 22: 636–640PubMedGoogle Scholar
  17. Harris RE, Alshafie GA, Abou-Issa H, Seibert K (2000) Chemo-prevention of breast cancer in rats by celecoxib, a cyclooxy-genase 2 inhibitor. Cancer Res 60: 2101–2113PubMedGoogle Scholar
  18. Hartmann LC, Schaid DJ, Woods JE et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Eng J. Med 340:77–84Google Scholar
  19. Hellriegel KP, Schulz KD (1995) Nachsorge bei Mammakarzi-nompatientinnen. Empfehlung einer Konsensus-Tagung. Berlin 23.–24.Februar 1995. Onkologe 1: 211–214,405–412Google Scholar
  20. Hellriegel KP, Schulz KD (1996) Nachsorge von Mammakarzi-nompatientinnen. Münch Med Wschr 138:99–101Google Scholar
  21. Henderson BE, Ross RK et al. (1988) Estrogens as a cause of human cancer. The Richard and Hilda Rosendahl Foundation Award Lecture. Cancer Res 48: 246–253PubMedGoogle Scholar
  22. Jasienska G, Thune I (2001) Lifestyle, hormones and risk of breast cancer. BMJ 322:586–587PubMedGoogle Scholar
  23. Josephson U, Wickman M, Sandelin K (2000) Initial experiences of women from hereditary breast cancer families after bilateral prophylactic mastectomy: a retrospective study. Eur J Surg Oncol 26 (4): 351–356PubMedGoogle Scholar
  24. Koller M, Kussmann J, Lorenz W et al. (1996) Symptomreorting in cancer patients: The role of negative affect and experienced social stigma. Cancer 77: 983PubMedGoogle Scholar
  25. Lorenz W (1998) Outcome: Definition and methods of evaluation. In: Troidl H, McKneally MF, Mulder DS et al. (eds) Surgical research: Basic principals and clinical practice, 3dr ed. New York: Springer: 513Google Scholar
  26. Meiser B, Butow P, Friedlander M et al. (2000) Intention to undergo prophylactic mastectomy in women at increased risk of developing heriditary breast cancer. J Clin Oncol 18 (11): 2250–2257PubMedGoogle Scholar
  27. Payne DK, Biggs C, Tran KN, Borgen PI, Massie MJ (2000) Women’s regret after bilateral prophylactic mastectomy. Ann Surg Oncol 7 (2): 150–154PubMedGoogle Scholar
  28. Peto J (2001) Cancer epidemiology in the last century and the next decade. Nature 411:390–395PubMedGoogle Scholar
  29. Powels T, Eeles R, Ashley S et al. (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352: 98–101Google Scholar
  30. Prentice R, Thompson D, Clifford C, Gorbach S, Goldin B, Byar D (1990) Dietary fat reduction and plasma estradiol concentration in healthy postmenopausal women. J Natl Cancer Inst 82:129–134PubMedGoogle Scholar
  31. Prout MN (2000) Breast cancer risk reduction: what do we know and where should we go? Medscape Womens Health 5: E4PubMedGoogle Scholar
  32. Rebbeck TR, Levin AM, Eisen A et al. (1999) Breast cancer risk after bilateral propylactic oophorectomy in BRCA1 mutation cariers. J Natl Cancer Inst 91:1475–1479PubMedGoogle Scholar
  33. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA (2001) Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93:358–366PubMedGoogle Scholar
  34. Rosenbaum Smith SM, Osborne MP (2000) Breast cancer che-moprevention. Am J Surg 180: 249–251Google Scholar
  35. Schiff R et al. (2000) Oxidative stress and AP-1 activity in ta-moxifen-resistant breast tumors in vivo. J Natl Cancer Inst 92:1926–1634PubMedGoogle Scholar
  36. Schrag D, Kuntz KM, Gaber JE, Weeks JC (1997) Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 and BRCA2 mutations. N Engl J Med 336:1465–1471PubMedGoogle Scholar
  37. Sieber WJ, Kaplan RM (2000) Informed Adherence: The need for shared medical decision making. Contolled Clinical Trails 21: 233–240Google Scholar
  38. Slattery M (2001) Does an Apple a Day Keep Breast Cancer Away? JAMA 285 (6): 799–801PubMedGoogle Scholar
  39. Smith-Warner SA, Spiegelman D, Yuan S et al. (2001) Intake of Fruit and Vegetables and Risk of Breast Cancer JAMA 285 (6): 769–776Google Scholar
  40. Sporn MB (1991) Carcinogenesis and cancer: different perspective on the same disease. Cancer Res 51: 6215–6218PubMedGoogle Scholar
  41. Sporn MB (1996) The war on cancer. Lancet 347:1377–1381PubMedGoogle Scholar
  42. Stalmeier PFM, Unic IJ, Verhoef LCG, Van Daal WAJ (1999) Evaluation of a shared decision making program for women suspected to have a genetic predisposition to breast cancer. Medical Decision Making 19: 230–241PubMedGoogle Scholar
  43. The Women’s Health Initiative Study Group (1998) Design of the Women’s Health Initiative clinical trial and observational Study. Control Clin Trials 19: 61–109Google Scholar
  44. Thune I, Brenn T, Lund E, Gaard M (1997) Physical activity and the risk of breast cancer. N Engl J Med 336:1269–1275PubMedGoogle Scholar
  45. Torrisi R, Decensi A (2000) Fenretinide and cancer prevention. Curr Oncol Rep 2: 263–270PubMedGoogle Scholar
  46. Vadlamui R et al. (1999) Regulation of cyclooxygenase 2 pathway by Her2 receptor. Oncogene 18:302–315Google Scholar
  47. Veronesi U, Maisonneuve P, Costa A et al. (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial hysterectomized women. Lancet 352: 93–97PubMedGoogle Scholar
  48. Weinsten JN (2000) The Missing Piece: Embracing Shared Decision Making to Reform Health Care. Spine 25:1–4Google Scholar
  49. Willett WC, Dietz WH, Colditz GA (1999) Guidelines for healthy weight. N Engl J Med 34: 427–34Google Scholar
  50. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Hennekens CH, Speizer FE (1997) Moderate alcohol consumption and the risk of breast cancer. N Engl J Med 336:1269–1275Google Scholar
  51. World Cancer Research Fund, American Institute for Cancer Research Expert Panel (1997) Food, Nutrition and the Prevention of Cancer: A Global Perspective. American Institute for Cancer Research Washington, DC, USAGoogle Scholar
  52. Wu AH, Pike MC, Stram DO (1999) Meta-analysis: dietary fat intake, serum estrogen levels, and the risk of breast cancer. J Natl Cancer Inst 91:529–534PubMedGoogle Scholar
  53. Yang LM, Tin U C, Wu K, Brown P (1999) Role of retinoid receptor in the prevention and treatment of breast cancer. J Mammary Gland Biol Neoplasia 4:377–388PubMedGoogle Scholar
  54. Alexander FE, Anderson TJ, Brown HK et al (1999) 14 years follow-up from the Edinburgh randomised trial of breast-cancer screening. The Lancet 353:1903–1908Google Scholar
  55. American Joint Committee on Cancer (1997) Breast. In : AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Ra-ven Publisher: 171–180Google Scholar
  56. Andersson I, Aspegren K, Janzon L et al (1991) Mammographic screening and mortality from breast cancer: the Malmö mammographie screening trial. British Medical Journal 297: 943–948Google Scholar
  57. Andersson I, Janzon L (1997) Reduced breast cancer mortality in women under age 50: Updated results from the Malmö mammographie screening program. Monogr Natl Cancer Inst 22:63–67PubMedGoogle Scholar
  58. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland (1999) Krebs in Deutschland. Saarland, 2. aktualisierte Auflage. Saarbrücken: Braun Druck RiegelsbergGoogle Scholar
  59. Arbeitsgemeinschaft der wissenschaftlich-medizinischen Fachgesellschaften, Ärztliche Zentralstelle Qualitätssicherung (Hrsg) (2001) Das Leitlinien-Manual. Entwicklung und Implementierung von Leitlinien in der Medizin, 1. Auflage. ZaeFQ 95 (Suppl 1): 1–84Google Scholar
  60. Barton MB, Harris R, Fletcher SW (1999) Does This Patient have Breast Cancer? The Screening Clinical Breast Examination;: Should it be done? How? JAMA 282:1270–1280PubMedGoogle Scholar
  61. Bellach BM, Stein H. (eds) (1999) Die neue Gesundheitspolitik der Europäischen Union. München: Urban und VogelGoogle Scholar
  62. Bjurstam N, Björneid L, Duffy SW et al (1997) The Gothenburg breast screening trial. First results on mortality, incidence, and mode of detection for women ages 39–49 years at randomisation. Cancer 80: 2091–2099PubMedGoogle Scholar
  63. Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ (2000) Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990–8: comparison of observed with predicted mortality. BMJ 321: 665–669PubMedGoogle Scholar
  64. Bundesministerium für Familie, Senioren, Frauen und Jugend (Hrsg) (2001) Verbundprojekt zur gesundheitlichen Situation von Frauen in Deutschland, 1. Aufl. Berlin: Kohlhammer: 123–132Google Scholar
  65. Cady B, Michaelsen JS (2001) The Life-Sparing Potential of Mammographie Screening. Cancer 91:1699–1703PubMedGoogle Scholar
  66. Cancer Research Campaigne (1991) Fact Sheet 6.2. UKGoogle Scholar
  67. Engel J, Baumert J, Dirschedl P, Sauer H, Hölzel D (2000) Wirksamkeit der Selbstuntersuchung, Palpation und Mammographie zur Früherkennung des Mammakarzinoms: Erste Ergebnisse der Feldstudie München. GebFra 60:155–165Google Scholar
  68. Engel J, Baumert J, Sauer H, Hölzel D (2001a) Qualitätssicherung in der Onkologie am Beispiel Mammakarzinom der Feldstudie München. Onkologie 3:307–320Google Scholar
  69. Engel J, Nagel G, Breuer E et al. (2001b) Primary breast cancer therapy in six regions of Germany. Eur J Cancer, in press)Google Scholar
  70. Frischbier HJ, Hoeffken W, Robra BP (1994) Mammographie in der Krebsfrüherkennung. Stuttgart: EnkeGoogle Scholar
  71. Frisell J, Lidbrink E (1997) The Stockholm Mammographie Screening Trial: Risks and Benefits in Age Group 40–49 Years. Journal of the National Cancer Institute Monographs 22:49–51PubMedGoogle Scholar
  72. Glöser S (1998) Brustkrebsvorsorge: KBV und Kassen erproben Mammographie-Screening. Dt. Ärztebl.B 1538:31–36Google Scholar
  73. Gøtzsche PC, Olsen O (2000) Is screening for breast cancer with mammography justifiable? Lancet 355:129–134PubMedGoogle Scholar
  74. Gøtzsche PC, Olsen O (2001) Cochrane review on screening for breast cancer with mammography. Lancet 358:1340–1342PubMedGoogle Scholar
  75. Hellriegel KP, Schulz K-D (1995) Nachsorge bei Mammakarzi-nom-Patientinnen. Empfehlungen einer Konsensus-Tagung. Forum DKG 10: 272Google Scholar
  76. Hendrick RE, Smith RA, Rutledge III JH et al (1997) Benefit of Screening Mammography in Women Aged 40–49: A New Meta-Analysis of Randomized Controlled Trials. Journal of the National Cancer Institute Monographs 22: 87–92PubMedGoogle Scholar
  77. Heywang-Köbrunner S (2001) Planung der Deutschen Rönt-gengesellschaft und des Berufsverbandes zur Qualitätssicherung bei Mammographie. Radiologe 41:352–358PubMedGoogle Scholar
  78. Jatoi I (Hrsg) (1997) Breast Cancer Screening. Landes Bioscien-ce. Heidelberg, Texas: SpringerGoogle Scholar
  79. Kahl H et al. (1999) Utilization of health screening studies and measures for health promotion. Gesundheitswesen 61, Sonderheft 2:165Google Scholar
  80. Kunz R, Ollenschläger G, Raspe H, Jonitz G, Kolkmann FW (Hrsg.) (2000) Lehrbuch Evidenzbasierte Medizin in Klinik und Praxis. Köln: Deutscher ÄrzteverlagGoogle Scholar
  81. Lash TL, Silliman RA, Guadagnoli E, Mor V (2000) The effect of less than definitive Care on Breast Carcinoma Recurrence and mortality. Cancer 89:1739–1747PubMedGoogle Scholar
  82. Levin F, Lucchini F, La Vecchia C, Negri E (1999) Trends in Mortality from Cancer in the European Union, 1955–1994. Lancet 354:742Google Scholar
  83. Lorenz W (1998) Outcome:Definition and methods of evaluation. In: Troidl H., McKneally MF, Mulder DS, Wechsler AS (eds) Basic principles and clinical practice. Surgical research, 3rd ed. New York: Springer: 513Google Scholar
  84. Lorenz W, Troidl H, Solomkin JS, Nies C (1999) Second step: Testing-Outcome measurements. World J Surg 23:768PubMedGoogle Scholar
  85. Lorenz W et al. (2001) Das Leitlinien-Manual von AWMF und ÄZQ. ZaeFQ 95 (Supp 1): IGoogle Scholar
  86. Miller AB, To T, Baines CB et al (1997) The Canadian National Breast Screening Study: update on breast cancer mortality. Journal of the National Cancer Institute Monograph 22: 37–41Google Scholar
  87. Nabholz JM, Tonkin K, Aapro MS, Buzdar AU (2000) Breast Cancer Management. Application of Evidence to Patient Care. London: Martin Dunitz Ltd.Google Scholar
  88. National Cancer Institute (2000) SEER Cancer Statistics Review 1973–1997. http://www.seer.ims.nci.nih.gov Google Scholar
  89. Nyström L (2000) How effective is screening for breast cancer? Reduction in mortality should not be the only marker of success. BMJ 321:647–648PubMedGoogle Scholar
  90. Ollenschläger G (2000) Qualitätssicherung in der Medizin — wem nützt das? Med Klin 95:536–538Google Scholar
  91. Otten JDM, v. Deyck J, Peer PGM et al (1996) Long-term breast cancer screening in Niymegen, the Netherlands: The nine rounds from 1975–1992. J Epidimiol Commun Health 50:353–358Google Scholar
  92. Organising Committee and Collaborators (1996) Breast-cancer screening with mammography in women aged 40–49 years. International Journal of Cancer 68 (6): 693–699Google Scholar
  93. Palmiere C (2000) Breast Cancer Screening: Screening has to be combined with good surgical and oncological services. BMJ 321: 567Google Scholar
  94. Peer PGM, v. Dijck JAAM, Hendriks JHCL et al. (1993) Age-dependent growth rate of primary breast cancer. Cancer 71: 3547–3551PubMedGoogle Scholar
  95. Peto R, Boreham J, Clarke M, Davies C, Beral V (2000) UK and USA breast cancer deaths down 25% in year 2000 at age 20–69 years. Lancet 355:1822PubMedGoogle Scholar
  96. Perleth M (1998) Bewertung von Leitlinien für die klinische Praxis. In: Perleth M, Antes G (Hrsg) Evidenzbasierte Medizin — Wissenschaft im Praxisalltag. München: MMV Medizin Verlag: 66–74Google Scholar
  97. Perry N, Broeders M, de Wolf C, Tornberg S (2001) European Guidelines for Quality Assurance in Mammography Screening, 3rd ed. Luxembourg: European Communities PublicationGoogle Scholar
  98. Richtlinie des Bundesausschusses der Ärzte und Krankenkassen über die Früherkennung von Krebserkrankungen (Krebsfrüherkennungs-Richtlinie) in der Fassung vom 26.April 1976, zuletzt geändert am 25.Mai 1994 § 25 Abs. 2 und 3 SGB V. Bundesanzeiger (1994): 160Google Scholar
  99. Ries LAG, Kosary CL, Hankey BF et al. (1999) SEER Cancer Statistic Review, 1973–1996. Bethesda, Maryland, USA: National Cancer InstituteGoogle Scholar
  100. Rosen PP, Groshen S, Saigo PE et al. (1989) A long term follow-up study of survival in stage I and stage II breast carcinoma. J Clin Oncol 7:355–366PubMedGoogle Scholar
  101. Sachverständigenrat für die Konzertierte Aktion im Gesundheitswesen (2001) Bedarfgerechtigkeit und Wirtschaftlichkeit, Bd I:11–45; Bd II: 47–96; http://www.svr.de Google Scholar
  102. Segura JM, Castell X, Casamitjana M, Macia F, Ferrer F (2000) Utilization of screening mammography as a preventive practice prior to iniating a population-based breast cancer screening-program. J Clin Epidemiol 53:595–603PubMedGoogle Scholar
  103. Schulz KD (2000) Ärztlich Konzertierte Aktion und 10 Punkte-Programm zur Brustkrebs-Früherkennung in Deutschland. ZaeFQ 94:421–422Google Scholar
  104. Schulz KD, Duda VF, Schreer I, Heywang-Köbrunner S (1997) Möglichkeiten der Brustkrebs-Früherkennung. Gynäkologe 30:631–636Google Scholar
  105. Schulz KD, Kreienberg R, Fischer R, Albert U.-S.(Hrsg) (2001) Manual zur Leitlinie „Brustkrebs-Früherkennung in Deutschland“. http://www.senologie.org Google Scholar
  106. Shapiro S (1997) Periodic Screening for Breast Cancer: The HIP Randomized Controlled Trial. Monogr Natl Cancer Inst 22:27–30PubMedGoogle Scholar
  107. Smith RA (2000) Breast Cancer Screening among women younger than age 50: A current assessment of the issues. Cancer J Clin 50:312–336Google Scholar
  108. Sobin LH, Wittekind CH (eds) (1997) UICC TNM classification of malignant tumours, 5th ed. New York: Wiley-LissGoogle Scholar
  109. Tabar L, Fagerberg G, Chen H-H et al (1995) Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer 75: 2507–2517PubMedGoogle Scholar
  110. Tabar L, Vitak B, Chen HHT, Yen MF, Duffy SW, Smith RA (2001) Beyond randomized controlled trials. Cancer 91:1742–1731Google Scholar
  111. Thurfjell EL, Lindgren JA (1996) Breast cancer survival rates with mammographic screening: similar favorable survival rates for women younger and those older 50 years. Radiology 201:421–426PubMedGoogle Scholar
  112. Tobias JS, Houghton J, Henderson JC (eds) (2001) Breast Cancer: New Horizon in Research and Treatment. London: ArnoldGoogle Scholar
  113. Trial of Early Detection of Breast Cancer Group: 16-year mortality from breast cancer in the UK Trial of Early Detection of breast Cancer. Lancet 353:1909–1914Google Scholar
  114. Wilson JMG, Jungner G (1968) Principles and practice of screening for disease. Geneva: World Health Organisation, WHO Public Health Paper: 345Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • U.-S. Albert
  • K.-D Schulz

There are no affiliations available

Personalised recommendations